Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Window: India Extends Price Cap Exemption To Foreign Innovation

Executive Summary

Innovative medicines developed abroad and patented and launched in India could be entitled to unfettered pricing for a five-year period under new norms announced in the country. Orphan drugs could also qualify for such exemption, much to the concern of healthcare activists.
Advertisement

Related Content

India Pharma In 2019: Buy, Build And Beware (Patient Power And Amazon)
India's Device Price Cap Storm Rages On: New Stent Cap And Spotlight On Catheter Trade Margins

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel